Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss.

Moore GR, Laule C, Mackay A, Leung E, Li DK, Zhao G, Traboulsee AL, Paty DW.

J Neurol. 2008 Nov;255(11):1802-11. doi: 10.1007/s00415-008-0002-z. Epub 2008 Sep 24.

PMID:
18821049
2.

Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology.

Laule C, Leung E, Lis DK, Traboulsee AL, Paty DW, MacKay AL, Moore GR.

Mult Scler. 2006 Dec;12(6):747-53.

PMID:
17263002
3.

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group.

Neurology. 2006 Mar 28;66(6):894-900.

PMID:
16567708
4.

Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis.

Liu Y, Liu J, Tetzlaff W, Paty DW, Cynader MS.

Free Radic Biol Med. 2006 Mar 15;40(6):960-7. Epub 2005 Oct 17.

PMID:
16540391
5.

Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.

Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, Frank JA, Grossman R, Paty DW, Radue EW, Wolinsky JS.

AJNR Am J Neuroradiol. 2006 Feb;27(2):455-61. No abstract available.

6.

Disability progression in multiple sclerosis is slower than previously reported.

Tremlett H, Paty D, Devonshire V.

Neurology. 2006 Jan 24;66(2):172-7.

PMID:
16434648
7.

The use of MRI as an outcome measure in clinical trials.

Li DK, Li MJ, Traboulsee A, Zhao G, Riddehough A, Paty D.

Adv Neurol. 2006;98:203-26. Review.

PMID:
16400836
8.

The natural history of primary progressive MS in British Columbia, Canada.

Tremlett H, Paty D, Devonshire V.

Neurology. 2005 Dec 27;65(12):1919-23.

PMID:
16380613
9.

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS.

Neurology. 2004 Nov 23;63(10):1788-95.

PMID:
15557491
10.

Treatment optimization in multiple sclerosis.

Freedman MS, Patry DG, Grand'Maison F, Myles ML, Paty DW, Selchen DH; Canadian MS Working Group.

Can J Neurol Sci. 2004 May;31(2):157-68. Review.

PMID:
15198439
11.

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.

Petkau AJ, White RA, Ebers GC, Reder AT, Sibley WA, Lublin FD, Paty DW; IFNB Multiple Sclerosis Study Group.

Mult Scler. 2004 Apr;10(2):126-38.

PMID:
15124756
12.

Water content and myelin water fraction in multiple sclerosis. A T2 relaxation study.

Laule C, Vavasour IM, Moore GR, Oger J, Li DK, Paty DW, MacKay AL.

J Neurol. 2004 Mar;251(3):284-93.

PMID:
15015007
13.

Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity.

Kastrukoff LF, Lau A, Wee R, Zecchini D, White R, Paty DW.

J Neuroimmunol. 2003 Dec;145(1-2):103-14.

PMID:
14644036
14.

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Neurology. 2003 Nov 25;61(10):1332-8. Review.

PMID:
14638950
15.

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.

Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, Shults CW, Stoessl AJ.

Exp Neurol. 2003 Nov;184 Suppl 1:S68-79. Review.

PMID:
14597329
16.

Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis.

Laule C, Vavasour IM, Whittall KP, Oger J, Paty DW, Li DK, MacKay AL, Arnold DL.

J Neurol. 2003 Aug;250(8):924-31.

PMID:
12928910
17.
18.

Interferons in relapsing remitting multiple sclerosis.

Paty D, Arnason B, Li D, Traboulsee A.

Lancet. 2003 May 24;361(9371):1822; author reply 1823-4. No abstract available.

PMID:
12781559
19.

Dendritic and synaptic pathology in experimental autoimmune encephalomyelitis.

Zhu B, Luo L, Moore GR, Paty DW, Cynader MS.

Am J Pathol. 2003 May;162(5):1639-50.

20.

Early onset multiple sclerosis: a longitudinal study.

Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D; University of British Columbia MS Clinic Neurologists.

Neurology. 2002 Oct 8;59(7):1006-10.

PMID:
12370453
21.
22.

The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver.

Gusev E, Boiko A, Bikova O, Maslova O, Guseva M, Boiko S, Vorobeichik G, Paty D.

Clin Neurol Neurosurg. 2002 Jul;104(3):203-7. No abstract available.

PMID:
12127655
23.

Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article].

Paty DW, Li DK; UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group.

Neurology. 2001 Dec;57(12 Suppl 5):S10-5. No abstract available.

PMID:
11902589
24.

Normal-appearing white matter in multiple sclerosis has heterogeneous, diffusely prolonged T(2).

Whittall KP, MacKay AL, Li DK, Vavasour IM, Jones CK, Paty DW.

Magn Reson Med. 2002 Feb;47(2):403-8.

25.

The lesions of multiple sclerosis.

Paty DW, Arnold DL.

N Engl J Med. 2002 Jan 17;346(3):199-200. No abstract available.

PMID:
11796856
26.

Genetic susceptibility to MS: a second stage analysis in Canadian MS families.

Dyment DA, Willer CJ, Scott B, Armstrong H, Ligers A, Hillert J, Paty DW, Hashimoto S, Devonshire V, Hooge J, Kastrukoff L, Oger J, Metz L, Warren S, Hader W, Power C, Auty A, Nath A, Nelson R, Freedman M, Brunet D, Paulseth JE, Rice G, O'Connor P, Duquette P, Lapierre Y, Francis G, Bouchard JP, Murray TJ, Bhan V, Maxner C, Pryse-Phillips W, Stefanelli M, Sadovnick AD, Risch N, Ebers GC.

Neurogenetics. 2001 Jul;3(3):145-51.

PMID:
11523565
27.

Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS.

Ann Neurol. 2001 Jul;50(1):121-7.

PMID:
11456302
28.

Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis.

Liu Y, Zhu B, Luo L, Li P, Paty DW, Cynader MS.

Neuroreport. 2001 Jul 3;12(9):1841-5.

PMID:
11435909
29.

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.

Li DK, Zhao GJ, Paty DW; University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group.

Neurology. 2001 Jun 12;56(11):1505-13.

PMID:
11402107
30.

T2 hyperintensities: findings and significance.

Li DK, Zhao G, Paty DW.

Neuroimaging Clin N Am. 2000 Nov;10(4):717-38 ,ix. Review.

PMID:
11359721
31.

A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain.

Moore GR, Leung E, MacKay AL, Vavasour IM, Whittall KP, Cover KS, Li DK, Hashimoto SA, Oger J, Sprinkle TJ, Paty DW.

Neurology. 2000 Nov 28;55(10):1506-10.

PMID:
11094105
32.

Ultrasound measurement of brain atrophy in multiple sclerosis.

Paty DW.

Arch Neurol. 2000 Sep;57(9):1264. No abstract available.

PMID:
11023451
33.

Defining the neurological basis of the Gulf War syndrome.

Rosenberg RN, Paty DW.

Arch Neurol. 2000 Sep;57(9):1263. No abstract available.

PMID:
10987891
34.

Analysis of effector CD4 (OX-40+) and CD8 (CD45RA+CD27-) T lymphocytes in active multiple sclerosis.

Hintzen RQ, Pot K, Paty D, Oger J.

Acta Neurol Scand. 2000 Jan;101(1):57-60.

PMID:
10660154
35.
36.

Recent developments in the assessment of quality of life in multiple sclerosis (MS).

Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D.

Mult Scler. 1999 Aug;5(4):251-9. Review.

PMID:
10467384
37.

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis.

Fazekas F, Barkhof F, Filippi M, Grossman RI, Li DK, McDonald WI, McFarland HF, Paty DW, Simon JH, Wolinsky JS, Miller DH.

Neurology. 1999 Aug 11;53(3):448-56. Review.

PMID:
10449103
39.

The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis.

Paty DW.

Neurology. 1999 Jul 22;53(2):437. No abstract available.

PMID:
10430451
40.

Cerebrospinal fluid concentrations of soluble CD27 in HTLV-I associated myelopathy and multiple sclerosis.

Hintzen RQ, Paty D, Oger J.

J Neurol Neurosurg Psychiatry. 1999 Jun;66(6):791-3.

41.

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.

Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G.

Neurology. 1999 Apr 12;52(6):1277-9.

PMID:
10214759
42.

Axonal cytoskeleton changes in experimental optic neuritis.

Zhu B, Moore GR, Zwimpfer TJ, Kastrukoff LF, Dyer JK, Steeves JD, Paty DW, Cynader MS.

Brain Res. 1999 Apr 10;824(2):204-17.

PMID:
10196450
43.

Lesion load reproducibility and statistical sensitivity of clinical trials in multiple sclerosis.

Cover KS, Petkau J, Li DK, Paty DW.

Neurology. 1999 Jan 15;52(2):433-5. No abstract available.

PMID:
9932990
44.

Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.

Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW.

Neurology. 1999 Jan 15;52(2):351-9.

PMID:
9932956
45.

A comparison between magnetization transfer ratios and myelin water percentages in normals and multiple sclerosis patients.

Vavasour IM, Whittall KP, MacKay AL, Li DK, Vorobeychik G, Paty DW.

Magn Reson Med. 1998 Nov;40(5):763-8.

PMID:
9797161
46.

A role for natural killer cells in the immunopathogenesis of multiple sclerosis.

Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW.

J Neuroimmunol. 1998 Jun 15;86(2):123-33.

PMID:
9663557
47.
48.

Anticytokine antibodies in beta-interferon-treated patients.

Sibley W, Paty D, Rice GP, Masuoka LK.

Neurology. 1998 Jun;50(6):1930-2. No abstract available.

PMID:
9633778
49.

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis.

Filippi M, Horsfield MA, Adèr HJ, Barkhof F, Bruzzi P, Evans A, Frank JA, Grossman RI, McFarland HF, Molyneux P, Paty DW, Simon J, Tofts PS, Wolinsky JS, Miller DH.

Ann Neurol. 1998 Apr;43(4):499-506.

PMID:
9546332

Supplemental Content

Support Center